Cell therapy (CAR-T) · Kills target cells, directed at CD19 and BCMA (TNFRSF17) · developed by Nanjing Legend Biotech
LCAR-AIO is a cell therapy of engineered T cells, described as CAR-T cells, that are given after a lymphodepleting conditioning regimen of cyclophosphamide and fludarabine. It is being studied in acute lymphoblastic leukemia, recurrent or refractory B-cell lymphoma, multiple sclerosis, neuromyelitis optica spectrum disease, MOG antibody-associated disorders and myasthenia gravis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06869278 | Phase 1 | Multiple Sclerosis (MS) | Withdrawn | LEGN |
| NCT05292898 | Phase 1 | Acute Lymphocytic Leukemia | Terminated | LEGN |
| NCT05318963 | Phase 1 | B-cell Lymphoma Recurrent | Terminated | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Lymphocytic LeukemiaB-cell Lymphoma RecurrentB-cell Lymphoma RefractoryMultiple Sclerosis (MS)Myasthenia GravisNeuromyelitis Optica Spectrum Disease (NMOSD)
Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.
See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LEGN catalysts and pipeline →